Global Cell Therapy Raw Materials Market Size Likely to Grow at a CAGR of 18.9% By 2035

Market Size and Growth

The market size of the global cell therapy raw materials will be estimated at USD 5.2 billion in 2025 and is expected to grow to between USD 6.1 billion in 2026 and about USD 29.3 billion by 2035 with a current CAGR of 18.9% during the period of 2026 to 2035.

Cell Therapy Raw Materials Market Revenue and Trends

Cell therapy raw materials are made up of biological and chemical substances that are vital for the entire cell-based therapy process, including development, manufacturing, processing, and preservation. The raw materials include media for cell culture, sera and serum substitutes, growth factors, cytokines, enzymes, buffers, reagents, cryopreservation solutions, vectors, and GMP-grade consumables, which together support the isolation, expansion, modification, and storage of cells. They play a crucial role in research, clinical trials, and production processes of commercial scale in respect of cell viability, functionality, safety, and consistency. The massive procurement of certified raw materials is being propelled by the solid financial support from governments, biopharmaceutical firms, and venture capital, the growth of cell therapy production plants, and the expansion of contract development and manufacturing organizations (CDMOs). The technological breakthroughs that include the use of serum-free and xeno-free media, chemically defined reagents, and large-scale single-use bioprocessing systems are making a direct contribution to the market growth by offering the advantages of better consistency, safety, and regulatory compliance.

What are the Factors That Have a Significant Contribution to the Growth of the Cell Therapy Raw Materials market?

The cell therapy raw materials market is primarily driven by the growing product approvals. For instance, in March 2025, KACTUS announced that their GMP-grade Cas9 enzyme, one of the proteins and enzymes available for cell therapy, is absolutely crucial in the process of Bioheng Therapeutics’ wonderful UCAR-T cellular therapy development! Bioheng’s cutting-edge UCART cell product has reached a milestone by receiving the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) on March 1, 2025. The FDA green light marks a significant step forward for BioNTech, bringing their main pipeline to the world clinical stage and demonstrating the necessity of superior gene editing enzymes for the enhancement of the next-generation cell and gene therapies. KACTUS’ standing as an exceptional global supplier of high-quality, GMP-Grade Cas9 Enzyme, which is vital for the development of cell and gene therapy (CGT), is also endorsed.

Moreover, the cell therapy raw materials market is undergoing a major transformation due to the technological advances in raw materials and processes that are significantly increasing the overall quality of the pharmaceuticals manufactured through these processes. The cell culture media are getting better and better defined chemically, and they are getting serum-free and xeno-free and the high-purity growth factors, cytokines, and enzymes that are taking up room in the manufacturing process are all contributing to the lowering of the batch-to-batch variation as well as the increase of cell viability and performance. On the other side, process innovation is the automated manufacturing and closed-system operations, single-use bioprocessing technologies, and bioreactors that are all supporting large-scale production while effectively reducing contamination risks. Innovations in these technologies come with the need for raw materials that are of the highest standards, compliant with good manufacturing practices (GMP), and compatible with the latest advanced platforms.

Segment Insight

By Product

The antibodies segment is expected to hold the largest market share in 2025. The increase in demand is attributed to the essential role of antibodies in the processes of cell isolation, activation, selection, and quality control. Antibodies are extensively employed in cell sorting (for example, the identification of surface markers), activation of immune cells, phenotyping, and potency testing thus, they are crucial not only for CAR-T, CAR-NK, stem cell and other immune cell–based treatments but also for therapies in general. As the number of clinical trials and commercialization of cell therapy programs keeps on increasing, the necessity for high specificity, GMP-grade, and validated antibodies is growing steadily.

Regional Insights

The cell therapy raw materials market has been dominated by North America. The expansion can be attributed to the region’s prominence in cell and gene therapy research, trials, and manufacturing on a commercial scale. The US has a significant share of biopharmaceutical companies, academic research institutions, and contract development and manufacturing organizations (CDMOs), which ensures a continuous need for top-quality raw materials like cell culture media, supplements, reagents, antibodies, vectors, and consumables certified as GMP-grade.

Besides, the Asia Pacific market has the highest rate of growth in the cell therapy raw materials market. The accelerating growth of the region’s biotechnology ecosystem is fueled by increased investments in healthcare and the unfolding interest in cell and gene therapies.

Report Scope

Recent Developments

• In December 2024, BioCentriq has signed a long-term lease agreement with National Business Parks for a modern cell therapy manufacturing facility that will be the company’s new headquarters in Princeton. This new location in Princeton is an extension of BioCentriq’s presence in Newark, thereby forming a regional manufacturing network. The facility will receive an immediate $12 million capital investment for upgrading the facility, purchasing equipment, and enhancing business systems, which will further strengthen BioCentriq’s position in the cell therapy market and increase its capability to offer all-around development, manufacture, and quality control service solutions throughout its customers’ product lifecycle. (Source: https://www.roi-nj.com/2024/12/17/healthcare/biocentriq-expands-operations-and-secures-cell-therapy-manufacturing-facility-in-princeton/)

List of the prominent players in the Cell Therapy Raw Materials Market:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher
• Sartorius Stedim Biotech
• Actylis
• ACROBiosystems
• STEMCELL Technologies.
• Grifols S.A.
• Charles River Laboratories
• RoosterBio Inc.
• PromoCell GmbH
• AGC Biologics
• Johnson & Johnson
• Promega Corporation
• STEMPEUTICS RESEARCH PVT LTD
• Others

The Cell Therapy Raw Materials Market is segmented as follows:

By Product

• Media
• Cell Culture Supplements
• Sera
• Reagents & Buffers
• Antibodies
• Others

By End Use

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America